First Patient Dosed in Ph 1 Clinical Trial of AGX101
“TM4SF1 is an emerging cancer target with exciting features: expression in two compartments of the tumor, tumor cells and the tumor vasculature; broad expression in malignant cancers, but limited expression in normal tissue; and a novel internalization pathway enabling delivery of chemotherapeutic payloads directly to the nucleus of cells in the tumor environment,” said Paul Jaminet, co-founder and CEO of Angiex. “Building upon 20 years of biological research and through 12 years of drug development, Angiex has tailored AGX101 design to TM4SF1 biology. Preclinical studies have supported AGX101’s ability to attack cancers by multiple mechanisms of action, and demonstrated a broad therapeutic margin in animals. We believe AGX101 has potential to help clinical cancer patients, especially in indications with high unmet need. We are excited to announce that the first patient has been dosed in this first-in-human study of our novel TM4SF1 ADC, AGX101.”
Share:
More News
Thomas Guérinier, CEO and Co-founder of Inside Therapeutics: “The collaboration with OSE and MiNT provides us with a fantastic opportunity to demonstrate the uniqueness of our technology for the development of mRNA therapies from early development through to clinical trials and GMP production. The HexARN project fits perfectly with our
Thomas Mehrling, MD, PhD, CEO and Director of Helix, said “As co-founder of the Laevoroc companies, I’ve had the privilege of seeing LEUMUNA and GEMCEDA evolve from early scientific concepts into differentiated, first-in-class therapeutic candidates with real potential to transform cancer care. Their integration into Helix marks a strategic consolidation
“At Boundless, we’re committed to delivering innovative therapies for patients with oncogene-amplified cancers through disciplined execution,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “By prioritizing the novel combination of BBI-355 and BBI-825, along with our exciting Kinesin program, BBI-940, we’re concentrating our resources where we see
“Most of the PMB-102 trial participants relapsed after CD19 CAR T therapy and/or presented with CD19 negative tumors. PMB-CT01 could present a viable alternative option for patients facing this challenging scenario,” said Hazel Cheng PhD., COO of PMB. “We are deeply committed to the development of this first-in-class BAFFR CAR
